Pentwater Capital Management LP 89bio, Inc. Transaction History

Pentwater Capital Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$15.06 - $19.41 $112,950 - $145,575	7,500 Added 33.33%	30,000 $463,000
Q2 2023 Aug 14, 2023	SELL	$14.15 - $22.03 $672,125 - $1.05 Million	-47,500 Reduced 67.86%	22,500 $426,000
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $733,600 - $1.19 Million	70,000 New	70,000 $1.07 Million
Q2 2022 Aug 15, 2022	BUY	$2.09 - $4.02 $428,449 - $824,099	205,000 Added 1366.67%	220,000 $708,000
Q1 2022 May 16, 2022	SELL	$3.45 - $14.99 $293,250 - $1.27 Million	-85,000 Reduced 85.0%	15,000 $57,000
Q4 2021 Feb 11, 2022	BUY	$11.15 - $19.66 $44,600 - $78,640	4,000 Added 4.17%	100,000 $1.31 Million
Q2 2021 Aug 16, 2021	BUY	$17.42 - $28.0 $17,420 - $28,000	1,000 Added 1.05%	96,000 $1.8 Million
Q1 2021 May 17, 2021	BUY	$20.22 - $26.73 $40,440 - $53,460	2,000 Added 2.15%	95,000 $2.25 Million
Q3 2020 Nov 16, 2020	BUY	$24.34 - $38.82 $2.26 Million - $3.61 Million	93,000 New	93,000 $2.39 Million

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $387M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Pentwater Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Pentwater Capital Management LP with notifications on news.